Key Details
Price
$248.64Annual ROE
233.63%Beta
0.10Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
N/ARecent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
June 13, 2014Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
VANCOUVER, BC / ACCESSWIRE / November 28, 2024 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) ("Camino" or the "Company") is happy to share that, following its announcement on October 7, 2024 about the joint acquisition of the Puquios copper project ("Puquios") in Chile, it is planning a non-brokered private placement to raise up to CAD$2,000,000 (the "Financing"). This Financing will involve issuing up to 57,142,857 common shares of the Company (each referred to as a "Share") at a price of CAD$0.035 per Share.
COR is becoming more popular due to the strong performance of the U.S. Healthcare Solutions sector, which creates a positive outlook for the stock.
This is a comparison of how Cencora (COR) and Halozyme Therapeutics (HALO) have done in relation to their industry this year.
Cencora (COR) has reached its highest point in the last year, but can investors expect further increases? We will examine the company's fundamentals for insights.
The Zacks Style Scores help investors quickly identify highly-rated stocks that match their investment preferences. Here are some reasons to make the most of this tool.
On Wednesday, Cencora, Inc. reported that its sales for the fourth quarter of 2024 rose by 14.7% to reach $79.1 billion, surpassing the expected figure of $77.65 billion.
Cencora, Inc. (NYSE:COR) held its Q4 2024 Earnings Call on November 6, 2024, at 8:30 AM ET. The call featured company representatives including Bennett Murphy, Bob Mauch, and Laz Krikorian, along with participants from various financial institutions. The operator, Drew, welcomed everyone to the call.
While the revenue and earnings per share (EPS) for Cencora (COR) provide insight into its performance for the quarter ending September 2024, it could be helpful to look at how these important figures stack up against Wall Street predictions and last year's results.
Cencora (COR) reported quarterly earnings of $3.34 per share, which is higher than the Zacks Consensus Estimate of $3.21 per share. This is an increase compared to last year's earnings of $2.86 per share.
On Wednesday, drug distributor Cencora announced that it plans to buy Retina Consultants of America (RCA) for $4.6 billion in cash, which will allow it to access a network of eye specialists.
FAQ
- What is the primary business of Cencora?
- What is the ticker symbol for Cencora?
- Does Cencora pay dividends?
- What sector is Cencora in?
- What industry is Cencora in?
- What country is Cencora based in?
- When did Cencora go public?
- Is Cencora in the S&P 500?
- Is Cencora in the NASDAQ 100?
- Is Cencora in the Dow Jones?
- When does Cencora report earnings?
- Should I buy Cencora stock now?